TradeOrgs
  • Stocks
  • Screener
  • Backtest
  • Watchlist
  • Signals
  • Portfolio
  • Insights
  • Connect
Sign in
RELIANCE₹1,304.00▼ 0.70%TCS₹2,093.50▼ 6.61%HDFCBANK₹801.05▲ 6.29%ICICIBANK₹1,411.40▲ 13.64%INFY₹1,047.20▼ 14.35%HINDUNILVR₹2,201.20▲ 5.29%ITC₹289.95▲ 4.68%SBIN₹1,040.00▲ 7.17%BHARTIARTL₹1,910.40▲ 4.73%KOTAKBANK₹396.75▲ 4.13%LT₹4,026.60▲ 1.86%AXISBANK₹1,342.10▲ 6.92%ASIANPAINT₹2,737.80▲ 2.83%MARUTI₹14,366.00▲ 10.13%AAPL$308.63▼ 2.08%MSFT$390.49▼ 11.52%GOOGL$359.91▼ 0.54%AMZN$242.67▼ 5.40%NVDA$194.83▼ 12.56%META$582.90▼ 2.46%TSLA$393.45▼ 7.15%BRK-B$507.78▲ 7.69%JPM$334.47▲ 11.13%V$362.13▲ 14.12%
RELIANCE₹1,304.00▼ 0.70%TCS₹2,093.50▼ 6.61%HDFCBANK₹801.05▲ 6.29%ICICIBANK₹1,411.40▲ 13.64%INFY₹1,047.20▼ 14.35%HINDUNILVR₹2,201.20▲ 5.29%ITC₹289.95▲ 4.68%SBIN₹1,040.00▲ 7.17%BHARTIARTL₹1,910.40▲ 4.73%KOTAKBANK₹396.75▲ 4.13%LT₹4,026.60▲ 1.86%AXISBANK₹1,342.10▲ 6.92%ASIANPAINT₹2,737.80▲ 2.83%MARUTI₹14,366.00▲ 10.13%AAPL$308.63▼ 2.08%MSFT$390.49▼ 11.52%GOOGL$359.91▼ 0.54%AMZN$242.67▼ 5.40%NVDA$194.83▼ 12.56%META$582.90▼ 2.46%TSLA$393.45▼ 7.15%BRK-B$507.78▲ 7.69%JPM$334.47▲ 11.13%V$362.13▲ 14.12%

TradeOrgs shows market information and analyzes your own trading history. It does not place trades and is not investment advice.

Prices and listings are for information only. We are read-only against your broker account.

Technical signals (RSI, MACD, etc.) are educational readouts of public indicators — not recommendations.

Privacy Policy·© 2026 TradeOrgs

← All stocks

🇺🇸ATOS

Atossa Therapeutics, Inc. - Common Stock

NASDAQ
$2.12
▼ $2.73 (-56.3%)
Live· just now
delayed feed · not for order timing

Price history · 20-day (cyan) / 50-day (purple) avg

as of 02 Jul 2026
H $11.25L $1.70-80.4%
$11.25$9.34$7.43$5.52$3.61$1.7$2.12
RSI (14)
Intraday · 15-minBuy+15RSI 56UptrendMACD Bearishfor day-trading context — not advice

Technical signal

Sell-15
RSI (14)29
oversold 30overbought 70
Trend
Downtrend
MACD
Bullish
Bollinger
Within bands
vs 20-day
below
vs 50-day
below
vs 200-day
below
Support
$1.70
Resistance
$4.87
  • Price is below its 50-day average (medium-term weakness).
  • RSI is 29 — oversold, a level some traders read as a potential entry zone.

Signal backtest · 2025-09-29 → 2026-07-02

Strategy return
-1.7%
Buy & hold
-83.8%
Trades
2
Win rate
50%

$100,000.00 invested would be worth $98,292.10 (-1.7%) · Full backtester →

Hypothetical: go long when the signal turns Buy, exit when it turns Sell. Past indicator behavior is not a prediction — educational only, not advice.

About Atossa Therapeutics, Inc.· Biotechnology

source: yahoo

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in areas of significant unmet medical need in oncology in the United States. Its lead drug candidate is oral (Z)-endoxifen, a selective estrogen receptor modulator and selective estrogen receptor degrader currently in Phase 2 clinical development for the treatment and reduction of risk of breast cancer, as well as in other therapeutic areas. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is based in Seattle, Washington.

Sector
Healthcare
Industry
Biotechnology
Employees
16
Headquarters
Seattle, United States
www.atossatherapeutics.com ↗

Fundamentals· Diversified

demo data

Live data was unavailable (the free feed can be rate-limited or blocked by region/host), so sample figures are shown. Set FINNHUB_API_KEY for a reliable fallback.

Market cap
$1.57T
P/E
12.8
P/B
2.6
EPS
$29.04
Div yield
2.6%
Profit margin
19.2%
ROE
20.6%
Debt / Equity
0.01
Beta
0.70
52-week range
$260.09 – $464.44
52-week low · $260.090% of rangehigh · $464.44

Recent news

News sentiment:▲ Positive2↑ · 0↓ · 6–
  • ATOS: Raises up to $16.5 Million in Registered Direct Offering▲ Positive
    Zacks Small Cap Research · 01 Jul 2026
  • Atossa Therapeutics Announces Closing of Registered Direct Offering of up to $16.5 Million in Gross Proceeds— Neutral
    PR Newswire · 12 Jun 2026
  • Top Midday Decliners— Neutral
    MT Newswires · 11 Jun 2026
  • Atossa Therapeutics Launches $16.5 Million Registered Direct Offering

Educational technical indicators — not investment advice. TradeOrgs does not place trades.

Fundamental data is informational only — not investment advice.

▲ Positive
MT Newswires · 11 Jun 2026
  • Atossa Therapeutics Announces Registered Direct Offering of up to $16.5 Million in Gross Proceeds— Neutral
    PR Newswire · 11 Jun 2026
  • Atossa Therapeutics highlights Endoxifen progress as potential Breast Cancer treatment— Neutral
    Proactive · 10 Jun 2026
  • Sentiment is a keyword-based read of the headline — a rough signal, not advice.